JoVE Logo
Faculty Resource Center

Sign In

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

DOI :

10.3791/55440-v

March 8th, 2018

March 8th, 2018

7,489 Views

1Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 2Sherbrooke Molecular Imaging Center (CIMS), Université de Sherbrooke, 3Sherbrooke Institute of Pharmacology

Viral-derived peptides coupled to antibody-conjugates (ACs) is an approach gaining momentum due to the potential of delivering molecular payloads with increased tumor cell accumulation. Utilizing common methods to evaluate peptide conjugation, AC and payload intracellular accumulation, and tumor targeting, this protocol helps researchers during the key initial development phases.

Tags

Keywords Antibody conjugates

-- Views

Related Videos

article

Increasing cDNA Yields from Single-cell Quantities of mRNA in Standard Laboratory Reverse Transcriptase Reactions using Acoustic Microstreaming

article

Hydrophobic Salt-modified Nafion for Enzyme Immobilization and Stabilization

article

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

article

Production and Targeting of Monovalent Quantum Dots

article

Fabrication of a Functionalized Magnetic Bacterial Nanocellulose with Iron Oxide Nanoparticles

article

Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles

article

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

article

Fabrication of a Multiplexed Artificial Cellular MicroEnvironment Array

article

Synthesis of Multi-walled Carbon Nanotubes Modified with Silver Nanoparticles and Evaluation of Their Antibacterial Activities and Cytotoxic Properties

article

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved